Abbott Laboratories (ABT) ended the fourth quarter in line with estimates and received a stock rating upgrade from Argus. The company's stock witnessed a 10% jump over a week and its 2025 sales guidance and diabetes technology shines despite a 'middling' quarter. Investment in Abbott has been significantly increased with many new purchases by several groups, advisors, and wealth management firms. ABT shares also witnessed selling by different organizations and individuals recently. The company reported its Q4 and full-year 2024 results and provided the financial outlook for 2025. Furthermore, ABT's Q4 earnings and Q1 profit guidance fell behind the street view along with falling worldwide COVID-19 testing sales. Despite the selling actions, the ABT stock has seen strong growth in key segments and is now trading at a discounted Price/Book value. Notably, insiders have sold stock hinting at potential weaknesses. A consideration of its financials against the market shows that the stock is trending and has seen strong growth. The future looks bright for Abbott Laboratories with many expecting its stock price to rise. Many praise the company's robust pipeline, its focus on future-driven pharmaceutical and its organic growth and margin expansion which makes it a solid investment.
Abbott Laboratories ABT News Analytics from Wed, 14 Aug 2024 07:00:00 GMT to Sat, 01 Feb 2025 12:05:03 GMT -
Rating 4
- Innovation 6
- Information 6
- Rumor 2
